Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)

Small molecule

Also known as CH-5126766, RG 7304, RO5126766, VS 6766, PF-04554878, VS-6063

Approvedregulatory verdict

Evidence outlook

Approved: Ovarian Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Ovarian Cancer
Phase 2 (21)
Ovarian Cancer
NCT05512208 · University of Oklahoma
2023-02-06 – 2029-12 · Endometrioid Cancer, Mucinous Ovarian Cancer, High Grade Serous Ovarian Cancer, Cervical Cancer, Solid Tumor
What this study did
NCT07747506 · Verastem, Inc.
2026-08-03 – 2028-08-01 · Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
What this study did
NCT06682572 · Verastem, Inc.
2024-10-30 – 2027-10 · Low Grade Serous Ovarian Cancer, Ovarian Cancer
What this study did
NCT06394804 · Memorial Sloan Kettering Cancer Center
2024-04-29 – 2027-04 · Low-Grade Serous Ovarian Cancer
What this study did
Other / comorbidity
NCT07743554 · Girish Dhall, MD
2027-01-01 – 2032-01 · MPNST (Malignant Peripheral Nerve Sheath Tumor)
What this study did
NCT07126158 · Washington University School of Medicine
2026-04-10 – 2030-04-30 · Pancreatic Adenocarcinoma, Cancer of the Pancreas, Pancreas Cancer, Pancreatic Cancer
What this study did
NCT06495125 · Emory University
2024-07-31 – 2029-09-17 · Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
What this study did
NCT06487221 · Ryan H. Moy, MD, PhD
2024-10-28 – 2029-05-30 · Gastric Cancer, Stomach Cancer
What this study did
NCT02465060 · National Cancer Institute (NCI)
2015-08-17 – 2027-12-31 · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
What this study did
NCT06007924 · Memorial Sloan Kettering Cancer Center
2023-08-16 – 2027-08-16 · Thyroid Cancer
What this study did
NCT04331041 · Washington University School of Medicine
2021-08-24 – 2027-04-21 · Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma
What this study did
NCT05787561 · Memorial Sloan Kettering Cancer Center
2023-03-15 – 2027-03 · Mesonephric Gynecologic Cancer
What this study did
NCT04439331 · National Cancer Institute (NCI)
2015-11-19 – 2027-01-15 · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
What this study did
NCT03727880 · Lei Zheng
2019-06-04 – 2025-01-15 · Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
What this study did
NCT04720417 · Thomas Jefferson University
2021-01-26 – 2024-04-30 · Metastatic Uveal Melanoma
What this study did
NCT04620330 · Verastem, Inc.
2020-12-31 – 2023-12-12 · Non Small Cell Lung Cancer, KRAS Activating Mutation
What this study did
NCT02004028 · Verastem, Inc.
2013-12-12 – 2019-06-19 · Malignant Pleural Mesothelioma
What this study did
NCT01951690 · Verastem, Inc.
2013-09 – 2016-06 · Non Small Cell Lung Cancer, Lung Cancer
What this study did
NCT01870609 · Verastem, Inc.
2013-09 – 2016-01 · Malignant Pleural Mesothelioma
What this study did
Phase 1/2 (11)
Ovarian Cancer
NCT03287271 · Michael McHale
2018-02-06 – 2025-03-12 · Ovarian Cancer
What this study did
Other / comorbidity
NCT06630260 · Institute of Cancer Research, United Kingdom
2024-11-15 – 2030-09-30 · Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant, Malignant Primary Gliomas
What this study did
NCT07824960 · University of Virginia
2026-10-01 – 2030-04 · Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Carcinoma, Locally Advanced Pancreatic Cancer
What this study did
NCT06194929 · University of Utah
2024-03-20 – 2030-01-15 · Cutaneous Melanoma, Brain Metastases
What this study did
NCT05608252 · Adrienne G. Waks
2023-02-23 – 2028-12-31 · Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
What this study did
NCT07020221 · Verastem, Inc.
2025-06-24 – 2028-12 · Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS
What this study did
NCT05669482 · Verastem, Inc.
2023-03-22 – 2027-08-31 · KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic, Malignant Neoplasm of Pancreas
What this study did
NCT05200442 · University of Chicago
2022-08-22 – 2027-05-01 · Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Advanced Colorectal Carcinoma, Advanced Colorectal Adenocarcinoma
What this study did
NCT05074810 · Verastem, Inc.
2022-04-12 – 2027-04 · Non Small Cell Lung Cancer, KRAS Activating Mutation
What this study did
NCT05375994 · Verastem, Inc.
2022-08-01 – 2026-06-15 · Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung, Malignant Neoplastic Disease
What this study did
NCT02758587 · NHS Greater Glasgow and Clyde
2017-07-04 – 2021-12 · Carcinoma, Non-small-cell Lung, Mesothelioma, Pancreatic Neoplasms
What this study did
Phase 1 (18)
Ovarian Cancer
NCT03875820 · Institute of Cancer Research, United Kingdom
2017-12-12 – 2026-10-31 · NSCLC, Low Grade Serous Ovarian Cancer, Endometrioid Carcinoma, Pancreatic Cancer
What this study did
NCT02407509 · Royal Marsden NHS Foundation Trust
2013-06-17 – 2025-10-15 · Solid Tumours, Multiple Myeloma, Lung Cancer, Ovarian Cancer
What this study did
NCT01778803 · Verastem, Inc.
2013-02-26 – 2015-02-23 · Ovarian Cancer
What this study did
Other / comorbidity
NCT07318324 · M.D. Anderson Cancer Center
2026-05-13 – 2030-08-01 · Phase IB, Avutometinib, RAS Pathway, Endometrial
What this study did
NCT07778602 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2026-11-10 – 2029-12-23 · MGMT-unmethylated Glioblastoma (GBM), IDH Wildtype Glioblastoma
What this study did
NCT05636514 · Clinical Hub for Interventional Research (CHOIR)
2022-12-14 – 2027-12-30 · Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
What this study did
NCT05798507 · Emory University
2023-07-28 – 2027-12-03 · Glioblastoma, Recurrent Glioblastoma
What this study did
NCT06104488 · Memorial Sloan Kettering Cancer Center
2023-10-20 – 2026-11-03 · Refractory Cancer, CNS Tumors, CNS Tumor, Adult, CNS Tumor, Childhood, MAP Kinase Family Gene Mutation, NF1, Plexiform Neurofibroma, Low-grade Glioma, Optic Pathway Gliomas, Neuroblastoma, Primary Brain Tumor, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, Central Nervous System Tumor
What this study did
NCT03681483 · Memorial Sloan Kettering Cancer Center
2018-10-31 – 2024-07-08 · Advanced Non-small Cell Lung Cancer
What this study did
NCT04201145 · Raphael Bueno, MD
2020-09 – 2022-12-31 · Malignant Pleural Mesothelioma
What this study did
NCT05187169 · Verastem, Inc.
2021-12-16 – 2022-04-12 · Food Effect
What this study did
NCT02546531 · Washington University School of Medicine
2016-02-03 – 2021-01-11 · Advanced Solid Tumors, Solid Tumors, Pancreatic Cancer
What this study did
NCT02372227 · Verastem, Inc.
2015-01 – 2015-10 · Relapsed Malignant Mesothelioma
What this study did
NCT02913716 · Verastem, Inc.
2015-08 – 2015-09 · Healthy Subjects
What this study did
NCT01943292 · Verastem, Inc.
2013-09-02 – 2014-06-09 · Non Hematologic Cancers
What this study did
NCT00787033 · Verastem, Inc.
2008-12 – 2012-02 · Cancer
What this study did
NCT00773526 · Hoffmann-La Roche
2008-11 – 2011-09 · Neoplasms
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Ovarian Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Avutometinib / Defactinib (Avmapki Fakzynja Co-Pack): this drugApprovedSmall moleculeFAK, MEK1/2 and RAF (CRAF, BRAF)not yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)not yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Mirvetuximab Soravtansine (Elahere)ApprovedAntibody–drug conjugate—not yet gradedNo reviewed efficacy summary in this indication
NiraparibApprovedSmall moleculePARP1/2Reliable signal
NCT02655016: Progression Free Survival (Up to 34 months): Placebo 8.2 Months (95% CI 7.3 to 8.5) | Niraparib 13.8 Months (95% CI 11.5 to 14.9)
OlaparibApprovedSmall moleculePARPnot yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signalNo reviewed efficacy summary in this indication
Relacorilant (Lifyorli)ApprovedSmall moleculeGlucocorticoid receptorPartial signalNo reviewed efficacy summary in this indication
RucaparibApprovedSmall moleculePARP (poly ADP-ribose polymerase) enzymes, PARP1/2Reliable signalFeatured results are non-efficacy only in this race
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
DurvalumabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
GSK 5733584Phase 3——not yet gradedNo reviewed efficacy summary in this indication
Ifebemtinib
Phase 3(overall)
Small moleculeFAK
not yet graded(overall)
No reviewed efficacy summary in this indication
INCB123667Phase 3Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
Olvimulogene NanivacirepvecPhase 3Oncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
Raludotatug DeruxtecanPhase 3Antibody–drug conjugateCDH6 (Cadherin-6)not yet gradedNo reviewed efficacy summary in this indication
Rinatabart Sesutecan (Rina-S)Phase 3Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Sofetabart MipitecanPhase 3Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Torvutatug SamrotecanPhase 3Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
BirinapantPhase 2—IAP (inhibitor of apoptosis) proteinsnot yet gradedNo reviewed efficacy summary in this indication
Ixotatug VedotinPhase 2Antibody–drug conjugateClaudin 6 (CLDN6)not yet gradedNo reviewed efficacy summary in this indication
StenoparibPhase 2Small moleculePARP1/2, Tankyrase 1/2not yet gradedNo reviewed efficacy summary in this indication
COM701Phase 1/2Monoclonal antibodyPVRIG (CD112R)not yet gradedNo reviewed efficacy summary in this indication
REGN5668Phase 1/2Multispecific antibodyMUC16 x CD28not yet gradedNo reviewed efficacy summary in this indication
RezatapoptPhase 1/2Small moleculep53 reactivatornot yet gradedNo reviewed efficacy summary in this indication
TUB-040Phase 1/2Antibody–drug conjugateNaPi2b (sodium-dependent phosphate transporter, SLC34A2)not yet gradedNo reviewed efficacy summary in this indication
UbamatamabPhase 1/2Monoclonal antibodyMUC16 x CD3not yet gradedNo reviewed efficacy summary in this indication
27T51Phase 1Cell therapyMUC16not yet gradedNo reviewed efficacy summary in this indication
ABBV-901Phase 1UndisclosedFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
APG-2449Phase 1Small moleculeFAK / ALK / ROS1not yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
IDE-161Phase 1Small moleculePARGnot yet gradedNo reviewed efficacy summary in this indication
XmAb541Phase 1Multispecific antibodyClaudin 6 (CLDN6) x CD3not yet gradedNo reviewed efficacy summary in this indication
Luveltamab TazevibulinDiscontinuedAntibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(20 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Avutometinib/defactinib (Avmapki Fakzynja Co-Pack) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1Glioblastoma, Recurrent GlioblastomaActive not recruiting
Est. primary completion 2026-12-03 · NCT05798507 · CT.gov ↗
What to watch
2027 (7)
March 2027 (1)
Phase 2Mesonephric Gynecologic CancerActive not recruiting
Est. primary completion 2027-03 · NCT05787561 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Ovarian CancerRecruiting
Est. primary completion 2027-04 · NCT06394804 · CT.gov ↗
What to watch
August 2027 (2)
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2027-08-01 · NCT07747506 · CT.gov ↗
What to watch
Phase 2Thyroid CancerRecruiting
Est. primary completion 2027-08-16 · NCT06007924 · CT.gov ↗
What to watch
December 2027 (3)
Phase 2Ovarian CancerRecruiting
Est. primary completion 2027-12 · NCT05512208 · CT.gov ↗
What to watch
Phase 1/2Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05608252 · CT.gov ↗
What to watch
Phase 2Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma …Active not recruiting
Est. primary completion 2027-12-31 · NCT02465060 · CT.gov ↗
What to watch
2028 (6)
January 2028 (1)
Phase 1/2Cutaneous Melanoma, Brain MetastasesRecruiting
Est. primary completion 2028-01-15 · NCT06194929 · CT.gov ↗
What to watch
August 2028 (1)
Phase 1Phase IB, Avutometinib, RAS Pathway, EndometrialRecruiting
Est. primary completion 2028-08-01 · NCT07318324 · CT.gov ↗
What to watch
October 2028 (1)
Phase 3Ovarian CancerRecruiting
Est. primary completion 2028-10-15 · NCT06072781 · CT.gov ↗
What to watch
November 2028 (2)
Phase 1MGMT-unmethylated Glioblastoma (GBM), IDH Wildtype GlioblastomaNot yet recruiting
Est. primary completion 2028-11-10 · NCT07778602 · CT.gov ↗
What to watch
Phase 2Gastric Cancer, Stomach CancerRecruiting
Est. primary completion 2028-11-30 · NCT06487221 · CT.gov ↗
What to watch
December 2028 (1)
Phase 1/2Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRASRecruiting
Est. primary completion 2028-12 · NCT07020221 · CT.gov ↗
What to watch
2029 (4)
February 2029 (1)
Phase 2Advanced Colorectal CancerRecruiting
Est. primary completion 2029-02-01 · NCT06369259 · CT.gov ↗
What to watch
March 2029 (1)
Phase 2Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8Recruiting
Est. primary completion 2029-03-17 · NCT06495125 · CT.gov ↗
What to watch
April 2029 (1)
Phase 1/2Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Carcinoma, Locally Advanced Pancreatic CancerNot yet recruiting
Est. primary completion 2029-04 · NCT07824960 · CT.gov ↗
What to watch
September 2029 (1)
Phase 1/2Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant …Recruiting
Est. primary completion 2029-09-30 · NCT06630260 · CT.gov ↗
What to watch
2030 (1)
April 2030 (1)
Phase 2Pancreatic Adenocarcinoma, Cancer of the Pancreas, Pancreas Cancer, Pancreatic CancerRecruiting
Est. primary completion 2030-04-30 · NCT07126158 · CT.gov ↗
What to watch
2031 (1)
January 2031 (1)
Phase 2MPNST (Malignant Peripheral Nerve Sheath Tumor)Not yet recruiting
Est. primary completion 2031-01 · NCT07743554 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 June 2026Topline resultRAMP 205 updated results in first-line metastatic pancreatic cancer